Network meta-analysis
HbA1c below 7 percent
Type 2 diabetes (adults); background therapy: one or more non insulin glucose lowering drugs
weeks 20 to 36 (target week 26)Hypothetical (as if everyone stayed on treatment)Each dose separatelyOdds ratio
10
Randomized trials
16
Treatments
5,345
Participants
2,874
Events
In plain language
Across 10 trials with 5,345 participants, 10 of 15 treatments had a clearly better result than placebo on HbA1c below 7 percent, and for 5 the evidence could not tell them apart from placebo. The most favorable estimate was for Tirzepatide 10 mg subcutaneous once weekly: odds ratio 49.78 (95% credible interval 10.26 to 192).
Higher values favor the treatment. "Clearly" means the 95% credible interval excludes no difference. These are averages across trials; they do not say how any one person will respond. Not medical advice.
Network of trials
Each circle is a treatment; each line joins treatments that were randomized against each other in at least one trial.
Effects compared with Placebo
Odds ratio. Higher values favor the treatment.
| Treatment | Bayesian OR (95% CrI) | 95% prediction interval | Frequentist OR (95% CI) | Verdict |
|---|---|---|---|---|
| Tirzepatide 10 mg subcutaneous once weekly TIRZ_SC_10MG_QW | 49.78 (10.26 to 192) | 7.05 to 241 | 94.49 (26.80 to 333) | Better |
| Tirzepatide 15 mg subcutaneous once weekly TIRZ_SC_15MG_QW | 20.28 (4.69 to 63.94) | 3.26 to 81.95 | 35.87 (12.29 to 105) | Better |
| Semaglutide 1.0 mg subcutaneous once weekly SEMA_SC_1p0MG_QW | 14.46 (4.47 to 39.70) | 2.90 to 55.22 | 15.64 (6.99 to 35.02) | Better |
| Tirzepatide 5 mg subcutaneous once weekly TIRZ_SC_5MG_QW | 13.28 (3.12 to 41.29) | 2.19 to 53.28 | 23.47 (8.38 to 65.76) | Better |
| Semaglutide 14 mg oral once daily (original tablet) SEMA_PO_14MG_QD | 11.07 (3.68 to 23.26) | 2.39 to 33.98 | 15.48 (7.75 to 30.92) | Better |
| Liraglutide 1.8 mg subcutaneous once daily LIRA_SC_1p8MG_QD | 8.28 (2.57 to 20.90) | 1.79 to 29.06 | 10.66 (4.97 to 22.85) | Better |
| Dulaglutide 1.5 mg subcutaneous once weekly DULA_SC_1p5MG_QW | 8.05 (2.27 to 18.86) | 1.57 to 24.96 | 13.41 (6.15 to 29.24) | Better |
| IGlarLixi 2:1 pen subcutaneous once daily titrated IGLARLIXI2_SC_TIT_QD | 7.55 (2.07 to 18.67) | 1.41 to 25.38 | 10.69 (4.80 to 23.84) | Better |
| Semaglutide 7 mg oral once daily (original tablet) SEMA_PO_7MG_QD | 6.76 (1.75 to 16.49) | 1.21 to 22.51 | 10.16 (4.49 to 22.99) | Better |
| Dulaglutide 0.75 mg subcutaneous once weekly DULA_SC_0p75MG_QW | 6.26 (1.89 to 14.01) | 1.24 to 19.40 | 9.98 (4.68 to 21.30) | Better |
| Insulin glargine INS_GLARGINE | 3.09 (0.91 to 7.08) | 0.59 to 9.83 | 4.91 (2.27 to 10.62) | Unclear |
| Tirzepatide 1 mg subcutaneous once weekly TIRZ_SC_1MG_QW | 2.98 (0.74 to 8.96) | 0.50 to 11.78 | 5.10 (1.81 to 14.35) | Unclear |
| Semaglutide 3 mg oral once daily (original tablet) SEMA_PO_3MG_QD | 2.18 (0.61 to 5.36) | 0.42 to 7.26 | 3.29 (1.46 to 7.38) | Unclear |
| Sitagliptin SITAGLIPTIN | 1.81 (0.41 to 5.09) | 0.31 to 6.98 | 2.69 (1.10 to 6.61) | Unclear |
| Lixisenatide 20 ug subcutaneous once daily LIXI_SC_20UG_QD | 1.61 (0.59 to 3.45) | 0.37 to 5.26 | 1.92 (1.01 to 3.63) | Unclear |
Ranking
How likely each treatment is to be among the best. Rankings ignore the size of differences and their certainty, so read them with the effects above.
League table
Every treatment against every other: odds ratio of the row treatment versus the column treatment, posterior median and 95% credible interval. Green: row clearly better; red: row clearly worse.
| Row versus column | PLACEBO | TIRZ_SC_10MG_QW | TIRZ_SC_15MG_QW | SEMA_SC_1p0MG_QW | TIRZ_SC_5MG_QW | SEMA_PO_14MG_QD | LIRA_SC_1p8MG_QD | DULA_SC_1p5MG_QW | IGLARLIXI2_SC_TIT_QD | SEMA_PO_7MG_QD | DULA_SC_0p75MG_QW | INS_GLARGINE | TIRZ_SC_1MG_QW | SEMA_PO_3MG_QD | SITAGLIPTIN | LIXI_SC_20UG_QD |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| PLACEBO | PLACEBO | 0.02 0.01 to 0.10 | 0.05 0.02 to 0.21 | 0.07 0.03 to 0.22 | 0.08 0.02 to 0.32 | 0.09 0.04 to 0.27 | 0.12 0.05 to 0.39 | 0.12 0.05 to 0.44 | 0.13 0.05 to 0.48 | 0.15 0.06 to 0.57 | 0.16 0.07 to 0.53 | 0.32 0.14 to 1.09 | 0.34 0.11 to 1.36 | 0.46 0.19 to 1.64 | 0.55 0.20 to 2.41 | 0.62 0.29 to 1.70 |
| TIRZ_SC_10MG_QW | 49.78 10.26 to 192 | TIRZ_SC_10MG_QW | 2.46 0.59 to 10.52 | 3.53 0.56 to 18.70 | 3.77 0.93 to 15.62 | 4.65 0.93 to 20.17 | 6.22 1.10 to 30.11 | 6.33 1.67 to 24.27 | 6.89 1.29 to 32.48 | 7.68 1.47 to 35.68 | 8.27 1.83 to 34.59 | 16.50 3.61 to 69.84 | 16.86 3.98 to 71.52 | 23.78 4.71 to 112 | 28.81 4.77 to 153 | 32.14 5.95 to 140 |
| TIRZ_SC_15MG_QW | 20.28 4.69 to 63.94 | 0.41 0.10 to 1.70 | TIRZ_SC_15MG_QW | 1.44 0.25 to 6.69 | 1.53 0.44 to 5.47 | 1.88 0.43 to 7.15 | 2.48 0.50 to 10.29 | 2.55 0.79 to 8.24 | 2.74 0.63 to 11.49 | 3.09 0.68 to 12.55 | 3.27 0.90 to 11.83 | 6.59 1.76 to 24.66 | 6.85 1.97 to 24.18 | 9.60 2.11 to 38.65 | 11.49 2.25 to 51.34 | 12.97 2.72 to 48.60 |
| SEMA_SC_1p0MG_QW | 14.46 4.47 to 39.70 | 0.28 0.05 to 1.80 | 0.69 0.15 to 4.08 | SEMA_SC_1p0MG_QW | 1.06 0.24 to 5.93 | 1.31 0.35 to 5.64 | 1.74 0.41 to 7.49 | 1.77 0.47 to 8.82 | 1.90 0.48 to 9.58 | 2.13 0.52 to 10.87 | 2.27 0.63 to 10.63 | 4.61 1.25 to 21.80 | 4.82 1.03 to 26.71 | 6.52 1.62 to 33.08 | 8.00 1.68 to 42.96 | 8.95 2.30 to 35.57 |
| TIRZ_SC_5MG_QW | 13.28 3.12 to 41.29 | 0.27 0.06 to 1.07 | 0.66 0.18 to 2.27 | 0.94 0.17 to 4.17 | TIRZ_SC_5MG_QW | 1.22 0.31 to 4.65 | 1.62 0.33 to 6.71 | 1.67 0.54 to 5.29 | 1.80 0.41 to 7.45 | 2.02 0.47 to 8.57 | 2.15 0.60 to 8.00 | 4.33 1.17 to 15.64 | 4.53 1.30 to 15.86 | 6.21 1.41 to 26.14 | 7.54 1.45 to 35.59 | 8.47 1.78 to 31.81 |
| SEMA_PO_14MG_QD | 11.07 3.68 to 23.26 | 0.22 0.05 to 1.07 | 0.53 0.14 to 2.31 | 0.76 0.18 to 2.89 | 0.82 0.22 to 3.26 | SEMA_PO_14MG_QD | 1.32 0.47 to 3.35 | 1.36 0.50 to 4.33 | 1.46 0.44 to 5.14 | 1.63 0.80 to 3.64 | 1.76 0.76 to 4.68 | 3.53 1.33 to 10.69 | 3.67 0.99 to 14.71 | 5.04 2.56 to 10.89 | 6.11 2.43 to 16.12 | 6.90 1.96 to 20.65 |
| LIRA_SC_1p8MG_QD | 8.28 2.57 to 20.90 | 0.16 0.03 to 0.91 | 0.40 0.10 to 2.01 | 0.58 0.13 to 2.45 | 0.62 0.15 to 2.99 | 0.76 0.30 to 2.13 | LIRA_SC_1p8MG_QD | 1.01 0.33 to 4.24 | 1.09 0.31 to 4.75 | 1.22 0.42 to 4.33 | 1.32 0.45 to 4.97 | 2.65 0.87 to 10.51 | 2.75 0.65 to 14.16 | 3.81 1.27 to 13.72 | 4.61 1.31 to 18.25 | 5.16 1.45 to 19.20 |
| DULA_SC_1p5MG_QW | 8.05 2.27 to 18.86 | 0.16 0.04 to 0.60 | 0.39 0.12 to 1.26 | 0.57 0.11 to 2.13 | 0.60 0.19 to 1.85 | 0.74 0.23 to 2.00 | 0.99 0.24 to 3.01 | DULA_SC_1p5MG_QW | 1.08 0.32 to 3.16 | 1.21 0.35 to 3.77 | 1.30 0.52 to 2.98 | 2.62 1.07 to 6.03 | 2.69 0.82 to 8.20 | 3.72 1.10 to 11.28 | 4.52 1.12 to 16.03 | 5.10 1.34 to 14.01 |
| IGLARLIXI2_SC_TIT_QD | 7.55 2.07 to 18.67 | 0.15 0.03 to 0.77 | 0.37 0.09 to 1.58 | 0.53 0.10 to 2.07 | 0.56 0.13 to 2.42 | 0.69 0.19 to 2.26 | 0.91 0.21 to 3.27 | 0.93 0.32 to 3.09 | IGLARLIXI2_SC_TIT_QD | 1.13 0.28 to 4.31 | 1.21 0.42 to 3.47 | 2.42 0.95 to 6.37 | 2.49 0.58 to 10.75 | 3.46 0.95 to 12.95 | 4.19 0.97 to 17.55 | 4.74 1.65 to 10.80 |
| SEMA_PO_7MG_QD | 6.76 1.75 to 16.49 | 0.13 0.03 to 0.68 | 0.32 0.08 to 1.48 | 0.47 0.09 to 1.93 | 0.49 0.12 to 2.11 | 0.61 0.27 to 1.24 | 0.82 0.23 to 2.39 | 0.83 0.27 to 2.84 | 0.89 0.23 to 3.54 | SEMA_PO_7MG_QD | 1.07 0.40 to 2.88 | 2.16 0.72 to 6.84 | 2.23 0.53 to 9.71 | 3.08 1.48 to 6.49 | 3.75 1.45 to 9.38 | 4.20 1.00 to 13.99 |
| DULA_SC_0p75MG_QW | 6.26 1.89 to 14.01 | 0.12 0.03 to 0.55 | 0.31 0.08 to 1.11 | 0.44 0.09 to 1.59 | 0.47 0.12 to 1.66 | 0.57 0.21 to 1.32 | 0.76 0.20 to 2.24 | 0.77 0.34 to 1.91 | 0.83 0.29 to 2.36 | 0.94 0.35 to 2.51 | DULA_SC_0p75MG_QW | 2.02 1.00 to 4.03 | 2.10 0.55 to 7.48 | 2.89 1.07 to 7.27 | 3.49 1.07 to 10.88 | 3.96 1.09 to 10.75 |
| INS_GLARGINE | 3.09 0.91 to 7.08 | 0.06 0.01 to 0.28 | 0.15 0.04 to 0.57 | 0.22 0.05 to 0.80 | 0.23 0.06 to 0.86 | 0.28 0.09 to 0.75 | 0.38 0.10 to 1.16 | 0.38 0.17 to 0.94 | 0.41 0.16 to 1.05 | 0.46 0.15 to 1.39 | 0.49 0.25 to 1.00 | INS_GLARGINE | 1.04 0.26 to 3.89 | 1.43 0.46 to 4.12 | 1.75 0.44 to 6.02 | 1.95 0.60 to 5.10 |
| TIRZ_SC_1MG_QW | 2.98 0.74 to 8.96 | 0.06 0.01 to 0.25 | 0.15 0.04 to 0.51 | 0.21 0.04 to 0.97 | 0.22 0.06 to 0.77 | 0.27 0.07 to 1.01 | 0.36 0.07 to 1.54 | 0.37 0.12 to 1.22 | 0.40 0.09 to 1.71 | 0.45 0.10 to 1.90 | 0.48 0.13 to 1.82 | 0.96 0.26 to 3.79 | TIRZ_SC_1MG_QW | 1.39 0.32 to 5.79 | 1.66 0.34 to 7.92 | 1.88 0.42 to 7.19 |
| SEMA_PO_3MG_QD | 2.18 0.61 to 5.36 | 0.04 0.01 to 0.21 | 0.10 0.03 to 0.47 | 0.15 0.03 to 0.62 | 0.16 0.04 to 0.71 | 0.20 0.09 to 0.39 | 0.26 0.07 to 0.79 | 0.27 0.09 to 0.91 | 0.29 0.08 to 1.06 | 0.33 0.15 to 0.68 | 0.35 0.14 to 0.93 | 0.70 0.24 to 2.17 | 0.72 0.17 to 3.08 | SEMA_PO_3MG_QD | 1.22 0.48 to 3.00 | 1.37 0.33 to 4.59 |
| SITAGLIPTIN | 1.81 0.41 to 5.09 | 0.03 0.01 to 0.21 | 0.09 0.02 to 0.44 | 0.12 0.02 to 0.59 | 0.13 0.03 to 0.69 | 0.16 0.06 to 0.41 | 0.22 0.05 to 0.76 | 0.22 0.06 to 0.89 | 0.24 0.06 to 1.03 | 0.27 0.11 to 0.69 | 0.29 0.09 to 0.93 | 0.57 0.17 to 2.26 | 0.60 0.13 to 2.98 | 0.82 0.33 to 2.09 | SITAGLIPTIN | 1.13 0.25 to 4.14 |
| LIXI_SC_20UG_QD | 1.61 0.59 to 3.45 | 0.03 0.01 to 0.17 | 0.08 0.02 to 0.37 | 0.11 0.03 to 0.44 | 0.12 0.03 to 0.56 | 0.15 0.05 to 0.51 | 0.19 0.05 to 0.69 | 0.20 0.07 to 0.75 | 0.21 0.09 to 0.60 | 0.24 0.07 to 1.00 | 0.25 0.09 to 0.92 | 0.51 0.20 to 1.67 | 0.53 0.14 to 2.40 | 0.73 0.22 to 3.01 | 0.88 0.24 to 4.04 | LIXI_SC_20UG_QD |
Heterogeneity, fit and convergence
Bayesian random effects (primary)
Frequentist check (netmeta)
Inconsistency
Do trials comparing two treatments directly agree with the indirect evidence through other treatments?
No comparison here has both direct and indirect evidence, so inconsistency cannot be checked by node splitting; the between designs Q above is the global check.
Small study effects
A comparison adjusted funnel plot: each point is one trial comparison, centered on its own network estimate. Asymmetry can signal that small trials with unfavorable results are missing.
Fewer than ten trial comparisons, too few to judge funnel plot asymmetry.
Baseline characteristics of the trials
The baseline value of each effect modifier or prognostic factor that applies here, per trial: mean or percent over arms, weighted by the number randomized. A note under a value names a stand in (a median for a mean, 100 minus the male share, Asian subgroup rows, an all Asian site list); "not reported" means no source of the trial prints it.
| Trial | Baseline HbA1c (percent) effect modifier, prognostic factor; 10 of 10 | Background glucose lowering therapy (stratum S0 to S4) effect modifier, prognostic factor; 10 of 10 | Diabetes duration (years) effect modifier, prognostic factor; 10 of 10 |
|---|---|---|---|
| NCT03131687 S000010 | 8.13 | S1 | 8.51 |
| PIONEER 4 S000133 | 7.98 | S1 | 7.6 |
| NCT01476475 S000191 | 8.05 | S1 | 6.7 |
| PIONEER 10 S000234 | 8.31 | S1 | 9.36 |
| NCT01584232 S000246 | 8.05 | S1 | 8.85 |
| SUSTAIN 9 S000483 | 8.05 | S1 | 9.7 |
| PIONEER 12 S000522 | 8.12 | S1 | 5.63 |
| AWARD-2 S001130 | 8.14 | S1 | 9.1 |
| LIXILAN JP-O1 S002018 | 8.39 | S1 | 8.67 |
| GETGOAL-M S002188 | 8.05 | S1 | 6.2 |
Comparability of the trials
Checked across designs (the set of treatments each trial compares) for eligibility, outcome definition and assessment, and the baseline factors above. Flags point to possible intransitivity; notes describe variation that is not tied to design.
- FlagBaseline, Diabetes duration: design means range from 5.6 (SEMA_PO_14MG_QD vs SEMA_PO_3MG_QD vs SEMA_PO_7MG_QD vs SITAGLIPTIN) to 9.7 (PLACEBO vs SEMA_SC_1p0MG_QW) years; threshold 3
- NoteOutcome assessment, time point: selected time points span 24 to 30 weeks
- NoteOutcome assessment, analysis set: mixed: full_analysis 5, modified_itt 5
- NoteOutcome assessment, definition: mixed: HbA1c below 7.0 percent 1, HbA1c below 7.0 percent, LOCF, mITT on treatment dataset 1, HbA1c below 7%; missing week 26 counted as nonresponder 1, not stated 7
- NoteOutcome assessment, proportion method: mixed: imputed 1, not stated 5, not_stated 3, observed 1
- NoteOutcome assessment, intercurrent events (discontinuation): mixed: hypothetical 7, not stated 3
- NoteOutcome assessment, intercurrent events (rescue): mixed: hypothetical 9, not stated 1
- NoteRisk of bias, blinding: mixed: double_blind 5, open_label 4, single_blind 1
- NoteData handling, input conversions: arms_combined 1, count_from_percent 9
| Trial | time weeks | analysis set | definition | instrument | adjudicated | proportion method | intercurrent events (discontinuation) | intercurrent events (rescue) | blinding | funding | start year | Eligibility |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT03131687 | 26 | modified_itt | HbA1c below 7.0 percent, LOCF, mITT on treatment dataset | not stated | not stated | imputed | hypothetical | hypothetical | double_blind | industry | 2017 | age 18 to 75; T2D at least 6 months; HbA1c 7.0 to 10.5%; BMI 23 to 50; diet and exercise or metformin |
| PIONEER 4 | 26 | full_analysis | not stated | not stated | not stated | observed | hypothetical | hypothetical | double_blind | industry | 2016 | Age 18 or older; T2D on metformin with or without SGLT2i; HbA1c 7.0 to 9.5 percent; eGFR 60 or more |
| NCT01476475 | 24 | modified_itt | not stated | not stated | not stated | not_stated | hypothetical | hypothetical | open_label | industry | 2011 | Adults with T2D; HbA1c 7 to 10 percent on metformin at least 1.5 g/day; insulin naive |
| PIONEER 10 | 26 | full_analysis | HbA1c below 7.0 percent | not stated | not stated | not stated | hypothetical | hypothetical | single_blind | industry | 2017 | Japanese adults 20 or older; T2D; HbA1c 7.0 to 10.5 percent on one oral glucose lowering drug |
| NCT01584232 | 26 | full_analysis | not stated | not stated | not stated | not stated | not stated | hypothetical | open_label | industry | 2012 | Japanese adults 20 years or older; BMI 18.5 to less than 35 kg/m2; HbA1c 7.0 to 10.0 percent; on sulfonylurea and/or biguanide |
| SUSTAIN 9 | 30 | full_analysis | not stated | not stated | not stated | not_stated | not stated | not stated | double_blind | industry | 2017 | adults 18 or older (20 in Japan); HbA1c 7.0 to 10.5 percent; stable SGLT2i with or without metformin or SU |
| PIONEER 12 | 26 | full_analysis | not stated | not stated | not stated | not stated | hypothetical | hypothetical | double_blind | industry | 2019 | adults with type 2 diabetes on metformin, HbA1c 7.0 to 10.5 percent |
| AWARD-2 | 26 | modified_itt | not stated | not stated | not stated | not stated | not stated | hypothetical | open_label | industry | 2010 | type 2 diabetes on metformin and glimepiride |
| LIXILAN JP-O1 | 26 | modified_itt | HbA1c below 7%; missing week 26 counted as nonresponder | not stated | not stated | not stated | hypothetical | hypothetical | open_label | industry | 2016 | insulin naive Japanese adults; HbA1c 7.5 to 10%; FPG 13.8 mmol/L or less; one or two OADs |
| GETGOAL-M | 24 | modified_itt | not stated | not stated | not stated | not_stated | hypothetical | hypothetical | double_blind | industry | 2008 | type 2 diabetes on metformin 1.5 g/day or more for 3 months; HbA1c 7 to 10 percent; FPG 13.9 mmol/L or less |
Trial data
What each trial contributes. Arm rows give the arm value with its standard error, or events over participants; contrast rows give the odds ratio on the analysis scale (log) against the trial's first row. Flags mark converted, combined or approximated inputs.
| Trial | Arm | Treatment | Week | Data | Value | SE | Events / N | Flags | Source |
|---|---|---|---|---|---|---|---|---|---|
| NCT03131687 | A1 | PLACEBO | 26 | arm, responders | 6 / 51 | R0016215:Supplement Table 4 | |||
| NCT03131687 | A2 | TIRZ_SC_1MG_QW | 26 | arm, responders | 17 / 52 | R0016215:Supplement Table 4 | |||
| NCT03131687 | A3 | TIRZ_SC_5MG_QW | 26 | arm, responders | 38 / 55 | R0016215:Supplement Table 4 | |||
| NCT03131687 | A4 | TIRZ_SC_10MG_QW | 26 | arm, responders | 45 / 50 | R0016215:Supplement Table 4 | |||
| NCT03131687 | A5 | TIRZ_SC_15MG_QW | 26 | arm, responders | 41 / 53 | R0016215:Supplement Table 4 | |||
| NCT03131687 | A6 | DULA_SC_1p5MG_QW | 26 | arm, responders | 28 / 54 | R0016215:Supplement Table 4 | |||
| PIONEER 4 | A1 | SEMA_PO_14MG_QD | 26 | arm, responders | 172 / 238 | count_from_percent | R0015836:Figure 2C | ||
| PIONEER 4 | A2 | LIRA_SC_1p8MG_QD | 26 | arm, responders | 160 / 245 | count_from_percent | R0015836:Figure 2C | ||
| PIONEER 4 | A3 | PLACEBO | 26 | arm, responders | 18 / 112 | count_from_percent | R0015836:Figure 2C | ||
| NCT01476475 | A1 | IGLARLIXI2_SC_TIT_QD | 24 | arm, responders | 135 / 160 | count_from_percent | registry:outcomes | ||
| NCT01476475 | A2 | INS_GLARGINE | 24 | arm, responders | 126 / 161 | count_from_percent | registry:outcomes | ||
| PIONEER 10 | A1 | SEMA_PO_3MG_QD | 26 | arm, responders | 58 / 126 | R0018421:Table 4 | |||
| PIONEER 10 | A2 | SEMA_PO_7MG_QD | 26 | arm, responders | 94 / 124 | R0018421:Table 4 | |||
| PIONEER 10 | A3 | SEMA_PO_14MG_QD | 26 | arm, responders | 101 / 120 | R0018421:Table 4 | |||
| PIONEER 10 | A4 | DULA_SC_0p75MG_QW | 26 | arm, responders | 45 / 62 | R0018421:Table 4 | |||
| NCT01584232 | A1 | DULA_SC_0p75MG_QW | 26 | arm, responders | 127 / 178 | R0016159:Results | |||
| NCT01584232 | A2 | INS_GLARGINE | 26 | arm, responders | 82 / 179 | R0016159:Results | |||
| SUSTAIN 9 | A1 | SEMA_SC_1p0MG_QW | 30 | arm, responders | 119 / 151 | count_from_percent | R0021710:Figure 2 | ||
| SUSTAIN 9 | A2 | PLACEBO | 30 | arm, responders | 29 / 151 | count_from_percent | R0021710:Figure 2 | ||
| PIONEER 12 | A1 | SEMA_PO_3MG_QD | 26 | arm, responders | 139 / 321 | R0019776:Table 2 | |||
| PIONEER 12 | A2 | SEMA_PO_7MG_QD | 26 | arm, responders | 213 / 315 | R0019776:Table 2 | |||
| PIONEER 12 | A3 | SEMA_PO_14MG_QD | 26 | arm, responders | 226 / 298 | R0019776:Table 2 | |||
| PIONEER 12 | A4 | SITAGLIPTIN | 26 | arm, responders | 122 / 334 | R0019776:Table 2 | |||
| AWARD-2 | A1 | DULA_SC_1p5MG_QW | 26 | arm, responders | 153 / 263 | registry:outcomes | |||
| AWARD-2 | A2 | DULA_SC_0p75MG_QW | 26 | arm, responders | 122 / 266 | registry:outcomes | |||
| AWARD-2 | A3 | INS_GLARGINE | 26 | arm, responders | 84 / 258 | registry:outcomes | |||
| LIXILAN JP-O1 | A1 | IGLARLIXI2_SC_TIT_QD | 26 | arm, responders | 105 / 161 | R0015751:Table 2 | |||
| LIXILAN JP-O1 | A2 | LIXI_SC_20UG_QD | 26 | arm, responders | 31 / 160 | R0015751:Table 2 | |||
| GETGOAL-M | A1+A2 | LIXI_SC_20UG_QD | 24 | arm, responders | 202 / 483 | count_from_percent;arms_combined | R0025872:Results | ||
| GETGOAL-M | A3 | PLACEBO | 24 | arm, responders | 36 / 164 | count_from_percent | R0025872:Results |
Rerun this analysis yourself
Remove treatments or trials and refit the frequentist and Bayesian models in your browser, with the same methods as the published analysis.